Searched for: in-biosketch:true
person:tanejs01
Penile, Urethral, and Scrotal Cancer
Taneja, Samir S
PMID: 27717441
ISSN: 1558-318x
CID: 2274342
The role of MRI in prostate cancer diagnosis and management
Mendhiratta, Neil; Taneja, Samir S; Rosenkrantz, Andrew B
Multiparametric MRI of the prostate demonstrates strong potential to address many limitations of traditional prostate cancer diagnosis and management strategies. Recent evidence supports roles for prostate MRI in prebiopsy risk stratification, guidance of targeted biopsy and preoperative disease staging. Prostate MRI may also assist the planning and follow-up of investigational partial gland ablative therapies. This article reviews the impact of prostate MRI on such diagnostic and therapeutic paradigms in contemporary prostate cancer management.
PMID: 27641839
ISSN: 1744-8301
CID: 2254742
Final Results of a Phase I/II Multicenter Trial of WST11 (TOOKAD(R) Soluble) Vascular-Targeted Photodynamic Therapy (VTP) for Hemiablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Conducted in the United States
Taneja, Samir S; Bennett, James; Coleman, Jonathan; Grubb, Robert; Andriole, Gerald; Reiter, Robert E; Marks, Leonard; Azzouzi, Abdel-Rahmene; Emberton, Mark
INTRODUCTION: Vascular targeted photodynamic therapy (VTP) with WST11 (TOOKAD(R) Soluble; STEBA Biotech, Luxembourg) is a form of tissue ablation that may be used therapeutically for localized prostate cancer (PCa). To study dosing parameters and associated treatment effects we undertook a prospective multicenter phase I/II trial of WST11 VTP for treatment of PCa METHODS: 30 men with unilateral, low volume, Gleason 3+3 PCa were enrolled at 5 centers following local IRB approval. Light energy, fiber number, and WST11 dose were escalated to identify optimal dosing parameters for VTP hemiablation. Men were treated by VTP and evaluated by post-treatment MRI and biopsy. PSA, light dose index (LDI -defined as sum of fiber length/ desired treatment volume), toxicity, and quality of life parameters were recorded. RESULTS: Following dose escalation, 21 men received optimized dosing of 4 mg/kg WST11 200 J energy. On post-treatment biopsy, residual PCa was found in the treated lobe in 10 men, untreated lobe in 4, and both lobes in 1. When LDI>/=1, at optimal dosing, (n=15), 73.3% had a negative biopsy in the treated lobe. Six men undergoing retreatment, with optimal dose and LDI >/=1, had negative post-treatment biopsy. Minimal effects on urinary, sexual function, and overall quality of life, were observed. CONCLUSIONS: Hemiablation of the prostate with WST11 VTP was well-tolerated and resulted in negative biopsy in the treated lobe for the majority of men. Dosing parameters and LDI appear related to tissue response as determined by MRI and biopsy. These parameters may serve as the basis for further prospective studies.
PMCID:5483996
PMID: 27291652
ISSN: 1527-3792
CID: 2144932
Re: Reevaluating PSA Testing Rates in the PLCO Trial
Taneja, Samir S
PMID: 27628793
ISSN: 1527-3792
CID: 2263892
Re: Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker with Outcomes and Survival in Castration-Resistant Prostate Cancer
Taneja, Samir S
PMID: 27628794
ISSN: 1527-3792
CID: 2263902
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial
Taneja, Samir S
PMID: 27628795
ISSN: 1527-3792
CID: 2263912
Predictive Value of Negative 3T Multiparametric Prostate MRI on 12 Core Biopsy Results
Wysock, James S; Mendhiratta, Neil; Zattoni, Fabio; Meng, Xiaosong; Bjurlin, Marc; Huang, William C; Lepor, Herbert; Rosenkrantz, Andrew B; Taneja, Samir S
OBJECTIVES: To evaluate the cancer detection rates (CDR) for men undergoing 12 core systematic prostate biopsy with negative prebiopsy mpMRI (NegMR). MATERIALS & METHODS: Clinical data from consecutive men undergoing prostate biopsy with prebiopsy 3T mpMRI from December 2011 to August 2014 were reviewed from an IRB approved prospective database. Prebiopsy mpMRI was read by a single radiologist and men with NegMR prior to biopsy were identified for this analysis. Clinical features, CDR, and NPV rates were summarized. RESULTS: Seventy five men underwent SPB with a NegMRI during the study period. For the entire cohort, men with no prior biopsy, men with prior negative biopsy, and men enrolled in active surveillance protocols, overall CDR was 18.7%, 13.8%, 8.0% and 38.1%, respectively, and detection of Gleason sum >/= 7 (GS>/=7) cancer was 1.3%, 0%, 4.0% and 0%, respectively. The NPV for all cancers was 81.3%, 86.2%, 92.0%, and 61.9%, and for GS>/=7 cancer was 98.7%, 100%, 96.0% and 100%, respectively. CONCLUSIONS: Negative prebiopsy mpMRI confers an overall NPV of 82% on 12 core biopsy for all cancer and 98% for GS>/=7. Based upon biopsy indication, these findings assist in prebiopsy risk stratification for detection of high risk disease and may provide guidance in the decision to pursue biopsy
PMID: 26800439
ISSN: 1464-410x
CID: 1922342
Re: Expectant Management of Veterans with Early-Stage Prostate Cancer
Taneja, Samir S
PMID: 27597067
ISSN: 1527-3792
CID: 2263882
Re: Racial Differences in the Surgical Care of Medicare Beneficiaries with Localized Prostate Cancer
Taneja, Samir S
PMID: 27597065
ISSN: 1527-3792
CID: 2263862
Re: Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men with Castration-Resistant Prostate Cancer
Taneja, Samir S
PMID: 27597066
ISSN: 1527-3792
CID: 2263872